Early access
Sign in
Not yet taking people in SpainPhase 3

Semaglutide for weight loss in obese adults waiting for a liver transplant

Tests semaglutide for weight loss and metabolic control in adults awaiting liver transplant.

Key facts

Who runs it
Fundacion Para La Formacion E Investigacion Sanitaria De La Region De Murcia
Where
Murcia, SpainSee the site
Registry title
Impact of Semaglutide in Liver Transplant Candidates with Obesity (SOMAL Study): A Prospective Randomized Study.
Status
Not yet recruiting
Phase
Phase 3
People taking part
50 people, planned
Started
2 Nov 2026
Expected to end
2 Nov 2030
Type of study
Interventional
Record updated
2 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with obesity who are candidates for a liver transplant. It tests semaglutide for weight loss and metabolic control.

Age
18 years or older
Sex
All sexes can join
Disease stage
Candidate for a liver transplant (on the active waiting list or being evaluated for the list). Expected time on the waiting list must allow at least 12 weeks of semaglutide before the transplant. BMI ≥ 30 kg/m², or ≥ 27 kg/m² with at least one metabolic condition (type 2 diabetes with HbA1c <8, high blood pressure, or dyslipidaemia).
Earlier treatment
People who had semaglutide within the last 6 months cannot join.

Main reasons for not taking part

  • Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2
  • Advanced chronic kidney disease (GFR <30 mL/min/1.73 m²)
  • CHILD C liver dysfunction
  • Pregnancy or breastfeeding
  • Type 2 diabetes with HbA1c ≥8

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • Age ≥ 18 years
  • Candidate for a liver transplant (on the active waiting list or being evaluated for inclusion on the list)
  • Body Mass Index (BMI) ≥ 30 kg/m², or ≥ 27 kg/m² with at least one metabolic comorbidity (type 2 diabetes mellitus with HbA1c <8, high blood pressure, dyslipidaemia)
  • Estimated time on the waiting list sufficient to complete at least 12 weeks of treatment with semaglutide prior to the transplant
  • The patient or their legal representative must sign the study’s informed consent form

Who cannot take part

  • Having received prior treatment with semaglutide within the last 6 months
  • Plan for a multi-organ transplant (e.g. liver-kidney) or a re-transplant
  • Absolute contraindication to the use of GLP-1 receptor agonists (personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2)
  • Upper gastrointestinal haemorrhage due to oesophageal varices
  • A history of acute or chronic pancreatitis
  • Severe disease-related malnutrition (according to GLIM criteria) or advanced sarcopenia (assessed by bioimpedance analysis: ASMMI: <5 in women and >7 in men)
  • Haemodynamic instability or an active, uncontrolled infection
  • Advanced chronic kidney disease (GFR <30 mL/min/1.73 m²)
  • Type 2 diabetes mellitus with HbA1c ≥8
  • Pregnancy or breastfeeding
  • Currently participating in, or having participated in, another clinical trial in the last 30 days
  • CHILD C liver dysfunction
  • Documented severe gastroparesis

Where in Spain

  • University Clinical Hospital Virgen De La ArrixacaMurcia, SpainNot yet recruiting

About the trial

What the trial wants to find out

To assess the efficacy and safety of semaglutide in liver transplant candidates in terms of weight loss and metabolic control.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Official title
Impact of Semaglutide in Liver Transplant Candidates with Obesity (SOMAL Study): A Prospective Randomized Study.
Plain-language title
Semaglutide for weight loss in obese adults waiting for a liver transplantGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
2 October 2026